Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.Rosenson RS, Elliott M, Stasiv Y, Hislop C; for the PLASMA II Investigators. Eur Heart J. 2010 Nov 16. [Epub ahead of print] |
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >=5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities.Koenig W, Ridker PM. Eur Heart J. 2011 Jan;32(1):75-83. |
Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial.Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Eur Heart J. 2010 Jul;31(13):1633-9. |
How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation.Cuende JI, Cuende N, Calaveras-Lagartos J. Eur Heart J. 2010 Oct;31(19):2351-8. |
Imaging of coronary atherosclerosis: intravascular ultrasound.Garcia-Garcia HM, Costa MA, Serruys PW. Eur Heart J. 2010 Oct;31(20):2456-69. |
C-reactive protein is a mediator of cardiovascular disease.Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. Eur Heart J. 2010 Sep;31(17):2087-91. |
C-reactive protein is a bystander of cardiovascular disease.Anand SS, Yusuf S. Eur Heart J. 2010 Sep;31(17):2092-6. |
Life-time risk factors and progression of carotid atherosclerosis in young adults: the Cardiovascular Risk in Young Finns studyJuonala M, Viikari JS, Kähönen M, Taittonen L, Laitinen T, Hutri-Kähönen N, et al. Eur Heart J. 2010 Jul;31(14):1745-51. |
Desenvolvido pela Diretoria de Tecnologia da SBC
Todos os Direitos Reservados © Copyright 2015
Sociedade Brasileira de Cardiologia | Tecnologia@cardiol.br